These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34185195)

  • 1. Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
    Abubakar M; Guo C; Koka H; Zhu B; Deng J; Hu N; Zhou B; Garcia-Closas M; Lu N; Yang XR
    Breast Cancer Res Treat; 2021 Sep; 189(2):483-495. PubMed ID: 34185195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
    Abubakar M; Figueroa J; Ali HR; Blows F; Lissowska J; Caldas C; Easton DF; Sherman ME; Garcia-Closas M; Dowsett M; Pharoah PD
    Mod Pathol; 2019 Sep; 32(9):1244-1256. PubMed ID: 30976105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
    Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
    Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication.
    Liu M; Tang SX; Tsang JYS; Shi YJ; Ni YB; Law BKB; Tse GMK
    J Clin Pathol; 2018 Dec; 71(12):1084-1089. PubMed ID: 30228212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
    Barton S; Zabaglo L; A'Hern R; Turner N; Ferguson T; O'Neill S; Hills M; Smith I; Dowsett M
    Br J Cancer; 2012 May; 106(11):1760-5. PubMed ID: 22531639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer.
    Tan W; Luo W; Jia W; Liang G; Xie X; Zheng W; Song E; Su F; Gong C
    Oncotarget; 2016 Dec; 7(52):87312-87322. PubMed ID: 27894097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
    Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
    Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.
    Rohan TE; Xue X; Lin HM; D'Alfonso TM; Ginter PS; Oktay MH; Robinson BD; Ginsberg M; Gertler FB; Glass AG; Sparano JA; Condeelis JS; Jones JG
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 24895374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.
    Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M
    J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
    Abubakar M; Chang-Claude J; Ali HR; Chatterjee N; Coulson P; Daley F; Blows F; Benitez J; Milne RL; Brenner H; Stegmaier C; Mannermaa A; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RAEM; Seynaeve C; Figueroa J; Lissowska J; Hewitt S; Hooning MJ; Hollestelle A; Foekens R; Koppert LB; ; Bolla MK; Wang Q; Jones ME; Schoemaker MJ; Keeman R; Easton DF; Swerdlow AJ; Sherman ME; Schmidt MK; Pharoah PD; Garcia-Closas M
    Int J Cancer; 2018 Aug; 143(4):746-757. PubMed ID: 29492969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Histopathological Markers with Clinico- Pathological Factors in Mexican Women with Breast Cancer.
    Bandala C; De la Garza-Montano P; Cortes-Algara A; Cruz-Lopez J; Dominguez-Rubio R; Gonzalez-Lopez JN; Cardenas-Rodriguez N; Alfaro-Rodriguez A; Salcedo M; Floriano-Sanchez E; Lara-Padilla E
    Asian Pac J Cancer Prev; 2015; 16(18):8397-403. PubMed ID: 26745092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
    Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P
    J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer.
    Lee J; Kim WH; Jung JH; Kim WW; Park CS; Lee RK; Park JY; Chae YS; Lee SJ; Kim HJ; Park JY; Park HY
    In Vivo; 2019; 33(6):2133-2139. PubMed ID: 31662548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China.
    Song Q; Huang R; Li J; Fan J; Zheng S; Zhang B; Yang H; Tang Z; He J; Xie X; Li H; Li J; Qiao Y
    PLoS One; 2013; 8(8):e72175. PubMed ID: 23977244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.
    Callagy GM; Pharoah PD; Pinder SE; Hsu FD; Nielsen TO; Ragaz J; Ellis IO; Huntsman D; Caldas C
    Clin Cancer Res; 2006 Apr; 12(8):2468-75. PubMed ID: 16638854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Value of IHC4 Score for Pathological Response to Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.
    Elsamany S; Elmorsy S; Alzahrani A; Rasmy A; Abozeed WN; Mohammed AA; Sherisher MA; Abbas MM; Mashhour M
    Asian Pac J Cancer Prev; 2015; 16(17):7975-9. PubMed ID: 26625828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study.
    Bao PP; Shu XO; Gao YT; Zheng Y; Cai H; Deming SL; Ruan ZX; Su Y; Gu K; Lu W; Zheng W
    Am J Epidemiol; 2011 Sep; 174(6):661-71. PubMed ID: 21768404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.